Crossmark

Future-Proofing European Pharmaceutical Regulatory and Market Access Practices Based on EU Learnings from the COVID-19 Pandemic: Insights from Multi-Stakeholder Interviews

Crossref DOI link: https://doi.org/10.1007/s43441-025-00855-2

Published Online: 2025-09-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Claessens, Zilke

Beirne, Grace

Decouttere, Catherine

Vandaele, Nico

Barbier, Liese

Huys, Isabelle
Funding

Funding for this research was provided by:

Fonds Wetenschappelijk Onderzoek (1S52125N, G086623N, G086623N, G086623N)

Innovative Medicines Initiative (101005077, 101005077, 101005077, 101005077)
License Information

Text and Data Mining valid from 2025-09-06

Version of Record valid from 2025-09-06
More Information

Article History

Received: 4 April 2025

Accepted: 29 July 2025

First Online: 6 September 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below